Condition
B-cell Lymphoma Refractory clinical trials and research
As of November 12, 2026, Find a Trial lists 5 B-cell Lymphoma Refractory clinical trials that are recruiting, at sites in 4 countries (most in China (2), South Korea (1), Singapore (1)). By phase: Phase 1 (2), Phase 1/2 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest B-cell Lymphoma Refractory clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Nanoparticle-delivered CAR1920 mRNA CAR‑T targeting CD19 and CD20 for relapsed or refractory B‑cell lymphoma/leukemia | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jan 7, 2026 |
| Antigen-targeted CAR T therapy for relapsed or high-risk B-cell lymphoma | Phase 1/2 | Singapore, Singapore | Recruiting | Jan 6, 2026 |
| Using Selinexor with ICE chemotherapy for B-cell lymphoma with CNS involvement | Phase 1/2 | Seoul and 1 other locations | Recruiting | Aug 14, 2024 |
| CAR-T cell therapy for adults with relapsed or refractory leukemia and lymphoma | Phase 1 | Nanchang, Jiangxi and 1 other locations | Recruiting | Jun 6, 2024 |
| CD19-targeted CAR‑T cell treatment for relapsed or refractory B‑cell leukemias and lymphomas | Phase 1 | São Paulo, São Paulo | Recruiting | Jan 31, 2023 |
All recruiting trials (5)
-
Nanoparticle-delivered CAR1920 mRNA CAR‑T targeting CD19 and CD20 for relapsed or refractory B‑cell lymphoma/leukemia
This trial tests whether polymer-lipid nanoparticles can deliver CAR1920 mRNA to program a patient's T cells to target CD19 and CD20 in people with relapsed or refractory B‑cell lymphoma or leukemia.
-
Antigen-targeted CAR T therapy for relapsed or high-risk B-cell lymphoma
This research will test a personalized CAR T-cell treatment that targets CD19, and sometimes CD22, in people with relapsed or high‑risk B‑cell lymphoma.
-
Using Selinexor with ICE chemotherapy for B-cell lymphoma with CNS involvement
This study is testing if adding Selinexor to standard chemotherapy can help people with B-cell lymphoma that has spread to the brain feel better when other treatments haven't worked.
-
CAR-T cell therapy for adults with relapsed or refractory leukemia and lymphoma
This study is testing a new CAR-T cell therapy to see if it can help adults with tough-to-treat leukemia or lymphoma feel better and fight their cancer.
-
CD19-targeted CAR‑T cell treatment for relapsed or refractory B‑cell leukemias and lymphomas
This study will try an experimental CD19-targeted CAR‑T cell therapy in children and adults whose CD19+ B‑cell leukemias or lymphomas have relapsed or not responded to at least two prior treatments.
Related topics
Quick answers
How many B-cell Lymphoma Refractory clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (2 trials), South Korea (1 trial), Singapore (1 trial), Brazil (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 2, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.